Stockreport

Atea Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update

Atea Pharmaceuticals, Inc. - common stock  (AVIR) 
PDF Topline SVR12 Results from Global Phase 2 Hepatitis C Virus (HCV) Study (N=275) Expected Q4’24 New Data Supportive of HCV Combination to be Presented at the American As [Read more]